Loading...
On May 23, 2014, the FDA announced the approval of dalbavancin (Dalvance) for treatment of acute bacterial skin and skin-structure infections (ABSSIs) caused by susceptible strains of Staphylococcus aureus, Streptococcus pyogenes, Streptococcus agalactiae, and Streptococcus anginosus–group organisms. In two phase III, randomized, controlled trials totaling >1300 patients, a two-dose regimen of intravenous dalbavancin (1000 mg on day 1 and 500 mg a week later) was noninferior to intravenous vancomycin (1000 mg or 15 mg/kg every 12 hours, with the option to switch to oral linezolid after 3 days) for this indication.
Dalbavancin is structurally related to vancomycin, with a similar spectrum of activity and potential for red-man syndrome if give…